Free Trial

Autonomix Medical (AMIX) Competitors

Autonomix Medical logo
$2.29 -0.05 (-2.14%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$2.26 -0.02 (-1.09%)
As of 05/1/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMIX vs. QTI, IRIX, XAIR, LFWD, VVOS, NRXS, PETV, CODX, BTCY, and PAVM

Should you be buying Autonomix Medical stock or one of its competitors? The main competitors of Autonomix Medical include QT Imaging (QTI), IRIDEX (IRIX), Beyond Air (XAIR), ReWalk Robotics (LFWD), Vivos Therapeutics (VVOS), NeurAxis (NRXS), PetVivo (PETV), Co-Diagnostics (CODX), Biotricity (BTCY), and PAVmed (PAVM). These companies are all part of the "medical equipment" industry.

Autonomix Medical vs.

Autonomix Medical (NASDAQ:AMIX) and QT Imaging (NASDAQ:QTI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Autonomix Medical had 8 more articles in the media than QT Imaging. MarketBeat recorded 8 mentions for Autonomix Medical and 0 mentions for QT Imaging. Autonomix Medical's average media sentiment score of 0.75 beat QT Imaging's score of 0.00 indicating that Autonomix Medical is being referred to more favorably in the media.

Company Overall Sentiment
Autonomix Medical Positive
QT Imaging Neutral

10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 24.2% of QT Imaging shares are held by institutional investors. 32.4% of Autonomix Medical shares are held by insiders. Comparatively, 75.4% of QT Imaging shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

QT Imaging's return on equity of 0.00% beat Autonomix Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Autonomix MedicalN/A -212.48% -161.13%
QT Imaging N/A N/A -65.94%

Autonomix Medical currently has a consensus price target of $16.50, suggesting a potential upside of 620.52%. Given Autonomix Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe Autonomix Medical is more favorable than QT Imaging.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autonomix Medical
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
QT Imaging
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Autonomix Medical received 2 more outperform votes than QT Imaging when rated by MarketBeat users.

CompanyUnderperformOutperform
Autonomix MedicalOutperform Votes
2
100.00%
Underperform Votes
No Votes
QT ImagingN/AN/A

Autonomix Medical has a beta of -3.08, suggesting that its stock price is 408% less volatile than the S&P 500. Comparatively, QT Imaging has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500.

QT Imaging has higher revenue and earnings than Autonomix Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autonomix MedicalN/AN/A-$15.43M-$12.93-0.18
QT Imaging$4.00M5.09-$4.03MN/AN/A

Summary

QT Imaging beats Autonomix Medical on 7 of the 13 factors compared between the two stocks.

Get Autonomix Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMIX vs. The Competition

MetricAutonomix MedicalSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$5.64M$4.33B$5.53B$7.93B
Dividend YieldN/A39.93%5.11%4.22%
P/E Ratio-0.1830.0322.5118.54
Price / SalesN/A55.31397.62103.30
Price / CashN/A51.0838.1834.62
Price / Book0.286.056.734.25
Net Income-$15.43M$68.71M$3.22B$248.18M
7 Day Performance10.10%-0.24%1.38%1.03%
1 Month Performance31.61%-2.90%2.79%2.70%
1 Year Performance-96.49%21.00%15.41%4.05%

Autonomix Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMIX
Autonomix Medical
3.4236 of 5 stars
$2.29
-2.1%
$16.50
+620.5%
-96.6%$5.64MN/A-0.181Analyst Forecast
QTI
QT Imaging
N/A$0.67
-5.0%
N/A-6.8%$18.04M$4.00M0.00N/AUpcoming Earnings
IRIX
IRIDEX
2.1268 of 5 stars
$1.02
-1.0%
$2.00
+96.1%
-58.5%$17.13M$48.67M-1.52120News Coverage
XAIR
Beyond Air
4.4548 of 5 stars
$0.22
-3.1%
$3.67
+1,536.9%
-81.4%$15.48M$3.02M-0.2170High Trading Volume
LFWD
ReWalk Robotics
2.5464 of 5 stars
$1.43
-0.3%
$9.00
+531.6%
-70.7%$14.94M$25.66M-0.5660
VVOS
Vivos Therapeutics
2.7903 of 5 stars
$2.26
+2.5%
$6.10
+170.5%
+9.2%$13.28M$15.03M-0.40160Short Interest ↓
NRXS
NeurAxis
N/A$1.90
+18.4%
N/A-32.2%$13.06M$2.69M-0.9819High Trading Volume
PETV
PetVivo
N/A$0.50
-3.8%
N/A-24.9%$12.11M$1.05M-1.1120Gap Down
CODX
Co-Diagnostics
4.3195 of 5 stars
$0.35
-1.2%
$1.00
+184.9%
-69.3%$11.78M$3.92M-0.25100Upcoming Earnings
Gap Up
BTCY
Biotricity
N/A$0.46
+7.0%
N/A-64.2%$11.46M$12.06M-0.4340Gap Up
PAVM
PAVmed
4.4103 of 5 stars
$0.67
+1.5%
$19.50
+2,832.3%
-64.5%$11.37M$3.00M-0.1590Short Interest ↓
Gap Up

Related Companies and Tools


This page (NASDAQ:AMIX) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners